The treatment of Helicobacter Pylori infection is a complex therapy consisting of antibiotics and proton pump inhibitors. Due to the developed resistance of H Pylori and the innate gastric mucosa barrier that limits the antibiotic penetration, more aggressive treatment regiments are now applied, with the current being as per the 4th Maastricht Consensus Conference.
Drawing from our internal expertise and understanding of the human biota, and it’s self regulating properties, a novel approach has been applied to the management of H.
Lactomezole, is a combination of a PPI and prebiotics. Its’ effectiveness is based on the bifidogenic affect of lactulose and the competitive inhibition of H. Pylori exerted by Bifidobacteria and Lactobacilli within the GI system.